Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2014 2
2015 1
2016 2
2017 1
2018 4
2019 2
2020 3
2021 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Therapy with pembrolizumab in treatment-naïve patients with nonmetastatic, mismatch repair deficient colorectal cancer.
Eefsen RL, Larsen JS, Klarskov LL, Altaf R, Høgdall E, Ingeholm P, Lykke J, Nielsen DL, Pfeiffer P, Poulsen LØ, Qvortrup C, Schou JV, Mau-Sørensen M, Østerlind K, Jensen BV. Eefsen RL, et al. Among authors: schou jv. Int J Cancer. 2023 May 15;152(10):2145-2152. doi: 10.1002/ijc.34420. Epub 2023 Jan 18. Int J Cancer. 2023. PMID: 36594580
The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer.
Meltzer S, Torgunrud A, Abrahamsson H, Solbakken AM, Flatmark K, Dueland S, Bakke KM, Bousquet PA, Negård A, Johansen C, Lyckander LG, Larsen FO, Schou JV, Redalen KR, Ree AH. Meltzer S, et al. Among authors: schou jv. Br J Cancer. 2021 Jul;125(2):240-246. doi: 10.1038/s41416-021-01377-y. Epub 2021 Apr 9. Br J Cancer. 2021. PMID: 33837301 Free PMC article.
Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?
Meltzer S, Bakke KM, Rød KL, Negård A, Flatmark K, Solbakken AM, Kristensen AT, Fuglestad AJ, Kersten C, Dueland S, Seierstad T, Hole KH, Lyckander LG, Larsen FO, Schou JV, Patrick Brown D, Abrahamsson H, Redalen KR, Ree AH. Meltzer S, et al. Among authors: schou jv. Clin Transl Radiat Oncol. 2019 Dec 2;21:5-10. doi: 10.1016/j.ctro.2019.11.006. eCollection 2020 Mar. Clin Transl Radiat Oncol. 2019. PMID: 31872084 Free PMC article.
Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer.
Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH. Kalanxhi E, et al. Among authors: schou jv. Br J Cancer. 2018 May;118(10):1322-1328. doi: 10.1038/s41416-018-0085-y. Epub 2018 Apr 26. Br J Cancer. 2018. PMID: 29695770 Free PMC article.
Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status.
Jensen BV, Schou JV, Yilmaz M, Johannesen HH, Skougaard K, Linnemann D, Hogdall EV, Larsen FO, Johansen JS, Pfeiffer P, Nielsen DL. Jensen BV, et al. Among authors: schou jv. Int J Cancer. 2021 May 15;148(10):2542-2556. doi: 10.1002/ijc.33448. Epub 2020 Dec 30. Int J Cancer. 2021. PMID: 33336394
17 results